Literature (Patient#)
Marsh et al 20137 (79) Allen et al 20181 (34) Furtado-Silva et al 201912 (118) Ali et al 20204 (36) Wustrau et al 20203 (60)
Serotherapy Campath Campath ATG/Campath: 86% ATG 67%; Campath 33% ATG/thymoglobulin 33%; Campath 67%
Alkylating agent
RICf (melphalan)
RIC (Melphalan)
MAC f (busulfan/Treosulfan) 90%; RIC (Melphalan) 10% MAC(Busulfan/CPM) 42%; RTC(Treosulfan/CPM) 25%; RIC(Melphalan) 33% Treosulfan/Thiotepa 75%; Melphalan/Thiotepa 27%
Stem cell source b BM 96%; PBSC 4% BM Cord BM 69%; PBSC 14%; Cord 17% BM 66%; PBSC 32%; Cord 2%
Donor c
Matched 75%; mismatch 25%. Sibling 24%; Unrelated 76%
MRD 21%; MUD 47%; MMUD 32% HLA-Match 6/6:30% HLA-Mis 5/6: 48% HLA-Mis ≤4/6: 22%
MRD 25%; MMRD 8%; MUD 50%; MMUD 17%
MRD 17%; MUD 37%; MMRD 10%; MURD 37%
2nd cell therapy d 19% 35% RTC 0%; MAC 13%; RIC 67% 32 %
EFS e g 6 yr: 34~69% 2 yr: RTC 89%; MAC 73%; RIC 42%
OS
1 yr: 80~91% 5 yr: 80~82%
1 yr: 82%; 18-month: 68%
6 yr: 55%
2 yr: RTC 89%; MAC 73%; RIC 83%
5 yr: 75%